Skip to main content
. 2022 Dec 25;10(6):2204932. doi: 10.1002/advs.202204932

Figure 6.

Figure 6

a) Schematic illustration of preparation of PMSN@OVA–MPN. b) Process of PMSN@OVA–MPN in vivo eliciting cellular immune responses via the MHC‐I pathway and generated CTL killing tumor cells. c) In vivo antitumor immunotherapeutic results. d) Evaluation of prophylaxis efficacy against an E.G7‐OVA tumor. Reproduced with permission.[ 140 ] Copyright 2020, American Chemical Society.